Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131

Tomas Cihlar, Adrian S. Ray, Constantine G. Boojamra, Lijun Zhang, Hon Hui, Genevieve Laflamme, Jennifer E. Vela, Deborah Grant, James Chen, Florence Myrick, Kirsten L. White, Ying Gao, Kuei Ying Lin, Janet Douglas, Neil T. Parkin, Anne Carey, Rowchanak Pakdaman, Richard L. Mackman

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

GS-9148 [(5-(6-amino-purin-9-yl)-4-fluoro-2,5-dihydro-furan-2-yloxymethyl) phosphonic acid] is a novel ribose-modified human immunodeficiency virus type 1 (HIV-I) nucleotide reverse transcriptase (RT) inhibitor (NRTI) selected from a series of nucleoside phosphonate analogs for its favorable in vitro biological properties including (i) a low potential for mitochondrial toxicity, (ii) a minimal cytotoxicity in renal proximal tubule cells and other cell types, (iii) synergy in combination with other antiretrovirals, and (iv) a unique resistance profile against multiple NRTI-resistant HIV-1 strains. Notably, antiviral resistance analysis indicated that neither the K65R, L74V, or M184V RT mutation nor their combinations had any effect on the antiretroviral activity of GS-9148. Viruses carrying four or more thymidine analog mutations showed a substantially smaller change in GS-9148 activity relative to that observed with most marketed NRTIs. GS-9131, an ethylalaninyl phosphonoamidate prodrug designed to maximize the intracellular delivery of GS-9148, is a potent inhibitor of multiple subtypes of HIV-1 clinical isolates, with a mean 50% effective concentration of 37 nM. Inside cells, GS-9131 is readily hydrolyzed to GS-9148, which is further phosphorylated to its active diphosphate metabolite (A. S. Ray, J. E. Vela, C. G. Boojamra, L. Zhang, H. Hui, C. Callebaut, K. Stray, K.-Y. Lin, Y. Gao, R. L. Mackman, and T. Cihlar, Antimicrob. Agents Chemother. 52:648-654, 2008). GS-9148 diphosphate acts as a competitive inhibitor of RT with respect to dATP (K i = 0.8 μM) and exhibits low inhibitory potency against host polymerases including DNA polymerase γ. Oral administration of GS-9131 to beagle dogs at a dose of 3 mg/kg of body weight resulted in high and persistent levels of GS-9148 diphosphate in peripheral blood mononuclear cells (with a maximum intracellular concentration of >9 μM and a half-life of >24 h). This favorable preclinical profile makes GS-9131 an attractive clinical development candidate for the treatment of patients infected with NRTI-resistant HIV.

Original languageEnglish (US)
Pages (from-to)655-665
Number of pages11
JournalAntimicrobial Agents and Chemotherapy
Volume52
Issue number2
DOIs
StatePublished - Feb 2008
Externally publishedYes

Fingerprint

Prodrugs
Nucleosides
HIV-1
Nucleotides
Reverse Transcriptase Inhibitors
Diphosphates
Organophosphonates
Proximal Kidney Tubule
Mutation
Ribose
RNA-Directed DNA Polymerase
DNA-Directed DNA Polymerase
GS-9148
GS-9131
Thymidine
Antiviral Agents
Oral Administration
Half-Life
Blood Cells
Body Weight

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131. / Cihlar, Tomas; Ray, Adrian S.; Boojamra, Constantine G.; Zhang, Lijun; Hui, Hon; Laflamme, Genevieve; Vela, Jennifer E.; Grant, Deborah; Chen, James; Myrick, Florence; White, Kirsten L.; Gao, Ying; Lin, Kuei Ying; Douglas, Janet; Parkin, Neil T.; Carey, Anne; Pakdaman, Rowchanak; Mackman, Richard L.

In: Antimicrobial Agents and Chemotherapy, Vol. 52, No. 2, 02.2008, p. 655-665.

Research output: Contribution to journalArticle

Cihlar, T, Ray, AS, Boojamra, CG, Zhang, L, Hui, H, Laflamme, G, Vela, JE, Grant, D, Chen, J, Myrick, F, White, KL, Gao, Y, Lin, KY, Douglas, J, Parkin, NT, Carey, A, Pakdaman, R & Mackman, RL 2008, 'Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131', Antimicrobial Agents and Chemotherapy, vol. 52, no. 2, pp. 655-665. https://doi.org/10.1128/AAC.01215-07
Cihlar, Tomas ; Ray, Adrian S. ; Boojamra, Constantine G. ; Zhang, Lijun ; Hui, Hon ; Laflamme, Genevieve ; Vela, Jennifer E. ; Grant, Deborah ; Chen, James ; Myrick, Florence ; White, Kirsten L. ; Gao, Ying ; Lin, Kuei Ying ; Douglas, Janet ; Parkin, Neil T. ; Carey, Anne ; Pakdaman, Rowchanak ; Mackman, Richard L. / Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131. In: Antimicrobial Agents and Chemotherapy. 2008 ; Vol. 52, No. 2. pp. 655-665.
@article{284ff3c1d3c04303af0999c60268f64a,
title = "Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131",
abstract = "GS-9148 [(5-(6-amino-purin-9-yl)-4-fluoro-2,5-dihydro-furan-2-yloxymethyl) phosphonic acid] is a novel ribose-modified human immunodeficiency virus type 1 (HIV-I) nucleotide reverse transcriptase (RT) inhibitor (NRTI) selected from a series of nucleoside phosphonate analogs for its favorable in vitro biological properties including (i) a low potential for mitochondrial toxicity, (ii) a minimal cytotoxicity in renal proximal tubule cells and other cell types, (iii) synergy in combination with other antiretrovirals, and (iv) a unique resistance profile against multiple NRTI-resistant HIV-1 strains. Notably, antiviral resistance analysis indicated that neither the K65R, L74V, or M184V RT mutation nor their combinations had any effect on the antiretroviral activity of GS-9148. Viruses carrying four or more thymidine analog mutations showed a substantially smaller change in GS-9148 activity relative to that observed with most marketed NRTIs. GS-9131, an ethylalaninyl phosphonoamidate prodrug designed to maximize the intracellular delivery of GS-9148, is a potent inhibitor of multiple subtypes of HIV-1 clinical isolates, with a mean 50{\%} effective concentration of 37 nM. Inside cells, GS-9131 is readily hydrolyzed to GS-9148, which is further phosphorylated to its active diphosphate metabolite (A. S. Ray, J. E. Vela, C. G. Boojamra, L. Zhang, H. Hui, C. Callebaut, K. Stray, K.-Y. Lin, Y. Gao, R. L. Mackman, and T. Cihlar, Antimicrob. Agents Chemother. 52:648-654, 2008). GS-9148 diphosphate acts as a competitive inhibitor of RT with respect to dATP (K i = 0.8 μM) and exhibits low inhibitory potency against host polymerases including DNA polymerase γ. Oral administration of GS-9131 to beagle dogs at a dose of 3 mg/kg of body weight resulted in high and persistent levels of GS-9148 diphosphate in peripheral blood mononuclear cells (with a maximum intracellular concentration of >9 μM and a half-life of >24 h). This favorable preclinical profile makes GS-9131 an attractive clinical development candidate for the treatment of patients infected with NRTI-resistant HIV.",
author = "Tomas Cihlar and Ray, {Adrian S.} and Boojamra, {Constantine G.} and Lijun Zhang and Hon Hui and Genevieve Laflamme and Vela, {Jennifer E.} and Deborah Grant and James Chen and Florence Myrick and White, {Kirsten L.} and Ying Gao and Lin, {Kuei Ying} and Janet Douglas and Parkin, {Neil T.} and Anne Carey and Rowchanak Pakdaman and Mackman, {Richard L.}",
year = "2008",
month = "2",
doi = "10.1128/AAC.01215-07",
language = "English (US)",
volume = "52",
pages = "655--665",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "2",

}

TY - JOUR

T1 - Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131

AU - Cihlar, Tomas

AU - Ray, Adrian S.

AU - Boojamra, Constantine G.

AU - Zhang, Lijun

AU - Hui, Hon

AU - Laflamme, Genevieve

AU - Vela, Jennifer E.

AU - Grant, Deborah

AU - Chen, James

AU - Myrick, Florence

AU - White, Kirsten L.

AU - Gao, Ying

AU - Lin, Kuei Ying

AU - Douglas, Janet

AU - Parkin, Neil T.

AU - Carey, Anne

AU - Pakdaman, Rowchanak

AU - Mackman, Richard L.

PY - 2008/2

Y1 - 2008/2

N2 - GS-9148 [(5-(6-amino-purin-9-yl)-4-fluoro-2,5-dihydro-furan-2-yloxymethyl) phosphonic acid] is a novel ribose-modified human immunodeficiency virus type 1 (HIV-I) nucleotide reverse transcriptase (RT) inhibitor (NRTI) selected from a series of nucleoside phosphonate analogs for its favorable in vitro biological properties including (i) a low potential for mitochondrial toxicity, (ii) a minimal cytotoxicity in renal proximal tubule cells and other cell types, (iii) synergy in combination with other antiretrovirals, and (iv) a unique resistance profile against multiple NRTI-resistant HIV-1 strains. Notably, antiviral resistance analysis indicated that neither the K65R, L74V, or M184V RT mutation nor their combinations had any effect on the antiretroviral activity of GS-9148. Viruses carrying four or more thymidine analog mutations showed a substantially smaller change in GS-9148 activity relative to that observed with most marketed NRTIs. GS-9131, an ethylalaninyl phosphonoamidate prodrug designed to maximize the intracellular delivery of GS-9148, is a potent inhibitor of multiple subtypes of HIV-1 clinical isolates, with a mean 50% effective concentration of 37 nM. Inside cells, GS-9131 is readily hydrolyzed to GS-9148, which is further phosphorylated to its active diphosphate metabolite (A. S. Ray, J. E. Vela, C. G. Boojamra, L. Zhang, H. Hui, C. Callebaut, K. Stray, K.-Y. Lin, Y. Gao, R. L. Mackman, and T. Cihlar, Antimicrob. Agents Chemother. 52:648-654, 2008). GS-9148 diphosphate acts as a competitive inhibitor of RT with respect to dATP (K i = 0.8 μM) and exhibits low inhibitory potency against host polymerases including DNA polymerase γ. Oral administration of GS-9131 to beagle dogs at a dose of 3 mg/kg of body weight resulted in high and persistent levels of GS-9148 diphosphate in peripheral blood mononuclear cells (with a maximum intracellular concentration of >9 μM and a half-life of >24 h). This favorable preclinical profile makes GS-9131 an attractive clinical development candidate for the treatment of patients infected with NRTI-resistant HIV.

AB - GS-9148 [(5-(6-amino-purin-9-yl)-4-fluoro-2,5-dihydro-furan-2-yloxymethyl) phosphonic acid] is a novel ribose-modified human immunodeficiency virus type 1 (HIV-I) nucleotide reverse transcriptase (RT) inhibitor (NRTI) selected from a series of nucleoside phosphonate analogs for its favorable in vitro biological properties including (i) a low potential for mitochondrial toxicity, (ii) a minimal cytotoxicity in renal proximal tubule cells and other cell types, (iii) synergy in combination with other antiretrovirals, and (iv) a unique resistance profile against multiple NRTI-resistant HIV-1 strains. Notably, antiviral resistance analysis indicated that neither the K65R, L74V, or M184V RT mutation nor their combinations had any effect on the antiretroviral activity of GS-9148. Viruses carrying four or more thymidine analog mutations showed a substantially smaller change in GS-9148 activity relative to that observed with most marketed NRTIs. GS-9131, an ethylalaninyl phosphonoamidate prodrug designed to maximize the intracellular delivery of GS-9148, is a potent inhibitor of multiple subtypes of HIV-1 clinical isolates, with a mean 50% effective concentration of 37 nM. Inside cells, GS-9131 is readily hydrolyzed to GS-9148, which is further phosphorylated to its active diphosphate metabolite (A. S. Ray, J. E. Vela, C. G. Boojamra, L. Zhang, H. Hui, C. Callebaut, K. Stray, K.-Y. Lin, Y. Gao, R. L. Mackman, and T. Cihlar, Antimicrob. Agents Chemother. 52:648-654, 2008). GS-9148 diphosphate acts as a competitive inhibitor of RT with respect to dATP (K i = 0.8 μM) and exhibits low inhibitory potency against host polymerases including DNA polymerase γ. Oral administration of GS-9131 to beagle dogs at a dose of 3 mg/kg of body weight resulted in high and persistent levels of GS-9148 diphosphate in peripheral blood mononuclear cells (with a maximum intracellular concentration of >9 μM and a half-life of >24 h). This favorable preclinical profile makes GS-9131 an attractive clinical development candidate for the treatment of patients infected with NRTI-resistant HIV.

UR - http://www.scopus.com/inward/record.url?scp=38649089790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38649089790&partnerID=8YFLogxK

U2 - 10.1128/AAC.01215-07

DO - 10.1128/AAC.01215-07

M3 - Article

VL - 52

SP - 655

EP - 665

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 2

ER -